Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCandriam Luxembourg S.C.A.
Latest Disclosed Ownership228,915 shares
Latest Disclosed Value $ 102,219,704
Candriam Luxembourg S.C.A. reports 1.61% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 30, 2026 - Candriam Luxembourg S.C.A. filed a 13F-HR form disclosing ownership of 228,915 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $102,219,704 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on April 30, 2026 disclosing 225,292 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 1.61% during the quarter. The current value of the position is $102,286,089 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 228,915 3,623 1.61 102,220 0.08 0.5310
2026-04-30 2025-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 225,292 50,725 29.06 102,143 49.40 0.5094
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 225,292 50,725 102,143 0.5086
2025-11-06 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 174,567 -1,831 -1.04 68,367 -12.95 0.3579
2025-08-08 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 176,398 -21,889 -11.04 78,536 -18.31 0.4528
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 198,287 -60,335 -23.33 96,134 -7.69 0.6021
2025-02-07 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 258,622 -52,685 -16.92 104,147 -28.06 0.5997
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 311,307 -16,964 -5.17 144,776 -5.90 0.8320
2024-08-05 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 328,271 -60,317 -15.52 153,860 -5.28 0.9326
2024-05-06 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 388,588 46,502 13.59 162,434 16.69 1.0388
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 342,086 -42,245 -10.99 139,198 4.15 0.9608
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 384,331 -12,231 -3.08 133,647 -4.23 0.9472
2023-08-08 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 396,562 5,654 1.45 139,554 23.10 1.0086
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 390,908 -78,237 -16.68 113,363 -16.32 0.7863
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 469,145 -15,394 -3.18 135,473 -3.44 0.9139
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 484,539 16,656 3.56 140,301 6.42 0.9884
2022-08-03 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 467,883 -6,370 -1.34 131,838 6.53 1.0856
2022-05-13 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 474,253 -170,379 -26.43 123,760 -12.58 0.8421
2022-02-10 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 644,632 51,803 8.74 141,562 31.65 0.9035
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 592,829 -215,038 -26.62 107,528 -33.99 0.7310
2021-07-20 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 807,867 28,321 3.63 162,890 -7.96 1.1150
2021-04-29 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 779,546 7 0.00 176,972 -3.95 1.4730
2021-01-22 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 779,539 221,408 39.67 184,244 21.32 1.4580
2020-10-19 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 558,131 11,940 2.19 151,872 -4.23 1.4267
2020-07-23 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 546,191 -179,170 -24.70 158,572 2.14 1.6738
2020-05-26 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 725,361 0 0.00 155,252 -2.25 1.7207
2020-02-05 2019-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 725,361 -205,638 -22.09 158,818 0.69 1.7022
2020-01-21 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 725,361 -205,638 159 1,705,276.7053
2020-02-05 2019-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 930,999 -9,507 -1.01 157,730 -8.14 2.0902
2019-10-21 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 930,999 -9,507 158 1,985,672.9923
2019-08-01 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 940,506 278,986 42.17 171,713 41.10 2.1416
2019-05-02 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 661,520 26,135 4.11 121,692 15.58 1.5568
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 635,385 177,234 38.68 105,285 19.23 1.6180
2018-11-07 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 458,151 131,345 40.19 88,304 58.97 1.1739
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 326,806 23,333 7.69 55,546 12.30 0.8790
2018-05-09 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 303,473 -52,302 -14.70 49,462 -7.23 0.8436
2018-02-07 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 355,775 -3,087 -0.86 53,316 -2.28 0.9224
2017-11-03 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 358,862 85,442 31.25 54,561 54.84 0.9532
2017-07-31 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 273,420 40,853 17.57 35,237 38.55 0.6622
2017-04-21 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 232,567 -24,851 -9.65 25,432 34.11 0.4923
2017-02-01 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 257,418 51,962 25.29 18,963 5.83 0.4351
2016-11-15 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 205,456 59,226 40.50 17,918 42.44 0.4309
2016-07-26 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 146,230 -11,289 -7.17 12,579 1.00 0.3271
2016-04-27 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 157,519 -85,643 -35.22 12,454 -59.30 0.3114
2016-01-25 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 243,162 -19,683 -7.49 30,597 11.77 0.8185
2015-10-19 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 262,845 -1,009 -0.38 27,374 -15.98 0.6721
2015-07-29 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 263,854 42,000 18.93 32,581 24.46 0.6781
2015-05-28 2015-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 221,854 20,332 10.09 26,178 9.34 0.5274
2015-04-27 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 221,854 26,172
2015-05-28 2014-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 201,522 201,522 23,941 0.5005
2015-03-26 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 201,522 201,522 23,941 0.4846
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.